The role of GPD2 on ferroptosis in sepsis-induced acute lung injury

share:

Brief intro:

  • Author: Ying Han, Chunfang Dai, DanDan Hu, Yu Yao, Wanwan Peng, Yijun Zheng, Qiyi Zeng, Hairui Xie, Jinda Huang
  • Journal: Biochemical and Biophysical Research Communications
  • Doi: https://www.doi.org/10.1016/j.bbrc.2025.153066
  • Publication Date: 2026/1/1

Products/Services used in the paper

Request Quote

Abstract

Sepsis-induced acute lung injury (ALI) is a serious complication that substantially increases mortality in sepsis. Glycerol-3-phosphate dehydrogenase 2 (GPD2), a mitochondrial enzyme, is involved in oxidative stress, inflammation, and ferroptosis. However, its specific role in sepsis-induced ALI remains unclear. This study explored the role of GPD2 in sepsis-induced ALI. The study employed a cecal ligation and puncture (CLP) mouse model of sepsis, with GPD2 expression knocked down using adeno-associated virus vectors. Selenomethionine (SeMet), a GPX4 activator, was administered 24 h prior to CLP surgery. Increased GPD2 expression was observed in the lungs of septic mice. GPD2 knockdown mice subjected to CLP had a reduced survival rate and exhibited exacerbated lung injury, characterized by increased vascular permeability, neutrophil infiltration, inflammation, and oxidative stress. Moreover, GPD2 knockdown significantly promoted ferroptosis in the lungs of septic mice. Notably, SeMet not only inhibited ferroptosis but also partially reversed the lung injury exacerbated by GPD2 knockdown in septic mice. Our results suggest that GPD2 may protect against pulmonary vascular permeability, neutrophil infiltration, oxidative stress, and inflammatory responses in septic mouse lung tissues by suppressing ferroptosis through the activation of the GPX4 pathway. These findings suggest that GPD2 could be a potential therapeutic target for sepsis-induced ALI.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download

Login

Don't have an account? Please register
Account*
Password*
Code*
Refresh
Forgot password?
Logging in indicates that you have read and accepted the Registration Agreement and User Agreement
Log in with other accounts

New User Registration

Already have an account?
First Name*
Middle Name
Last Name*
Organization*
Organization Type*
Country/State*
Email Address*
Set Password*
Confirm password*
Refferal Code*

Reset Password

Return to
Email*
Code*
New password*
Confirm password*

Google Account Binding

Organization*
Organization Type*
Country/State*